↓ Skip to main content

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Overview of attention for article published in Lancet Oncology, October 2016
Altmetric Badge
42

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
policy
2 policy sources
twitter
10 X users
patent
16 patents

Citations

dimensions_citation
589 Dimensions

Readers on

mendeley
369 Mendeley
citeulike
1 CiteULike